Sponsoring Agency HHS
    POP 9/20/12 - 9/19/14 (1 year)


The Division of Cancer Prevention (DCP) of the National Cancer Institute (NCI) has awarded a Master IDIQ for Preclinical In Vitro and In Vivo Agent Development Assays. This contract supports the development of potential cancer preventive agents using mechanism-based screening assays in vitro and in vivo. The screening assays will evaluate the potential of test agents to inhibit, reverse, or delay early carcinogenesis through a variety of endpoints, such as histopathology, pharmacokinetics, pharmacodynamics, molecular targets and pathways, transformation, proliferation, and apoptosis, using state-of-the-art experimental methodologies.

  • $9.8m Aggregate Dollars Obligated
  • $9.8m Aggregate Base & Exercised Options
  • $9.8m Aggregate Base & All Options (Ceiling)

Market Stats Related Contracts